Oxygen Biotherapeutics plans to sell common stock in public offering

Joint bookrunners Ladenburg Thalmann, MTS Securities assist with sale

By Devika Patel

Knoxville, Tenn., March 17 - Oxygen Biotherapeutics, Inc. plans a public sale of its common stock, according to a preliminary prospectus supplement filed Monday with the Securities and Exchange Commission.

Ladenburg Thalmann & Co. Inc. is the bookrunner, and MTS Securities, LLC is the co-manager.

Proceeds will be used for clinical trials, efforts to obtain regulatory approval for Levosimendan and Oxycyte, developing other product candidates, manufacturing of Levosimendan and Oxycyte, research and development and general corporate purposes.

The Morrisville, N.C., company develops biotechnology products with a focus on oxygen delivery to tissue.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.